Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Advanced Cell Diagnostics Inc. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, ensuring that no single examiner is responsible for the entire active portfolio. This distribution requires the company to manage interactions with multiple individuals at the patent office simultaneously.
The prosecution spans 2 distinct art units, reflecting a spread of the company's technology across different specialized groups within the office. SALMON, KATHERINE D is the busiest examiner, holding 1 pending action. Since there are 2 distinct examiners, each is managing a portion of the active cases. This split across 2 distinct art units indicates a decentralized prosecution environment. Practitioners must coordinate their efforts across these different groups to ensure consistent results for the company's patent applications. The 1 pending action under SALMON, KATHERINE D represents a specific portion of the active workload.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245660 | METHODS AND COMPOSITIONS FOR REMOVAL OF RNA | SALMON, KATHERINE D | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245660 | METHODS AND COMPOSITIONS FOR REMOVAL OF RNA | SALMON, KATHERINE D | 5d overdue |
| 17285825 | METHODS FOR DIGITAL MULTIPLEXING OF NUCLEIC ACIDS IN SITU | LU, FRANK WEI MIN | 5d |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18245660 | METHODS AND COMPOSITIONS FOR REMOVAL OF RNA | SALMON, KATHERINE D | 1682 | §103§112 | Non-Final OA | 5d overdue | Pending | Mar 16, 2023 |
| 17285825 | METHODS FOR DIGITAL MULTIPLEXING OF NUCLEIC ACIDS IN SITU | LU, FRANK WEI MIN | 1683 | §112 | Non-Final OA | 5d | Pending | Apr 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial